Development of a novel, nonimmunogenic, soluble human TNF receptor type I (sTNFR-I) construct in the baboon
Autor: | Amer Abouhamze, Jill Gasser, Lyle L. Moldawer, J. Frazier, Tadahiko Kohno, Angela Nelson, Carl K. Edwards, Steven W. Martin, William J. Boyle, James Ervin Seely, Olaf B Kinstler, Gary L. Kieft, Jeff Rose, Jason J. Rosenberg, Kunitaro Fukuzuka, William Marshall, Gregory C. Gaines, Ulrich Feige, Judy St. Clair |
---|---|
Rok vydání: | 2001 |
Předmět: |
Physiology
medicine.medical_treatment Molecular Sequence Data Enzyme-Linked Immunosorbent Assay Inflammation Receptors Tumor Necrosis Factor Etanercept Polyethylene Glycols law.invention Pharmacokinetics law Physiology (medical) biology.animal Escherichia coli medicine Animals Humans Amino Acid Sequence Cloning Molecular Receptor biology Tumor Necrosis Factor-alpha Immunogenicity Hemodynamics Blood Cell Count Kinetics Cytokine Immunoglobulin G Immunology Recombinant DNA Cytokines Tumor necrosis factor alpha medicine.symptom Half-Life Papio Baboon |
Zdroj: | Journal of Applied Physiology. 91:2213-2223 |
ISSN: | 1522-1601 8750-7587 |
DOI: | 10.1152/jappl.2001.91.5.2213 |
Popis: | Pharmacokinetics and immunogenicity of six different recombinant human soluble p55 tumor necrosis factor (TNF) receptor I (sTNFR-I) constructs were evaluated in juvenile baboons. The constructs included either an sTNFR-I IgG1 immunoadhesin (p55 sTNFR-I Fc) or five different sTNFR-I constructs covalently linked to polyethylene glycol. The constructs were administered intravenously three times, and pharmacokinetics and immunogenicity were examined over 63 days. All of the constructs were immunogenic, with the exception of a 2.6-domain monomeric sTNFR-I. To evaluate whether the nonimmunogenic 2.6-domain monomeric construct could protect baboons against TNF-α-induced mortality, baboons were pretreated with 1, 5, or 10 mg/kg body wt and were compared with baboons receiving either placebo or 1 mg/kg body wt of the dimeric 4.0-domain sTNFR-I construct ( n = 3 each) before lethal Escherichia colibacteremia. The monomeric construct protected baboons and neutralized TNF bioactivity, although greater quantities were required compared with the dimeric 4.0-domain sTNFR-I construct. We conclude that E. coli-recombinant-derived human sTNFR-I constructs can be generated with minimal immunogenicity on repeated administration and still protect against the consequences of exaggerated TNF-α production. |
Databáze: | OpenAIRE |
Externí odkaz: |